Project Grant R01CA289553
Award Date
9/10/24
Completion Date
8/31/29
Dollars Obligated
$490K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Penn State University, PA 16802, USA
Similar Awards
This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under CFDA Program 93.394 - Cancer Detection and Diagnosis Research, provides $1,453,091 in funding to develop and clinically evaluate an imaging-enabled, adaptable CAR T cell (IMAC) therapy platform. The University of Pennsylvania will lead this project, which aims to create a novel CAR T cell approach that can be monitored and controlled through PET imaging and targeted biologics. The goal is to enable safe and...
This federal Project Grant award of $568,151 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a real-time functional photoacoustic imaging platform to enable sensitive detection of prostate cancer tumors and accurate characterization of their aggressiveness. The key products and services to be delivered through this 5-year award include: Optimization of biocompatible polyacrylamide hydrogel nanoparticle (PAA NP) probes for...
The National Cancer Institute (NCI) awarded a $554,188 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Trustees of the University of Pennsylvania. The grant supports the development of novel silver telluride nanoparticle contrast agents for use in dual-energy mammography screening of breast cancer, particularly in women with dense breasts. Key activities include adapting the nanoparticle synthesis process for scalable microfluidic manufacturing,...
This Project Grant award from the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) to The Regents of the University of California, San Francisco (UCSF) aims to develop innovative molecular imaging strategies to identify mechanisms of resistance to immunotherapy in cancer patients. The $676,006 award, with a project period from January 1, 2025 to December 31, 2029, will support research to utilize PET imaging, implantable fluorescence sensors, and high-parameter...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) totaling $263,086 will fund the development of a multiparametric endoscopic ultrasound (MPEUS) imaging system to improve pancreatic cancer screening and characterization. The project will implement real-time MPEUS imaging in high-risk individuals enrolled in a pancreatic cancer screening program to assess the feasibility and benefits of this novel approach. As a secondary...
This $692,072 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund the development of a novel theranostic platform using PSMA-targeted poly(amidoamine) (PAMAM) dendrimers for the management of prostate cancer. The key products to be delivered include: PSMA-targeted theranostic agents that enable highly specific targeting, quantitative PET/CT imaging for patient selection, and delivery of potent antimitotic agents....
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Trustees of the University of Pennsylvania in the amount of $597,766 supports the development of novel dual-tracer PET imaging protocols to better characterize cancer. The key products and services to be delivered under this 5-year award include: Developing protocols to image fluoroglutamine (a research radiotracer of glutamine metabolism) in combination with FDG in breast...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $654,681 Project Grant to Case Western Reserve University to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The key objectives of this 5-year project are to: 1) Design and develop multifunctional ionizable lipid nanoparticle-based peptide vaccines for...
The National Cancer Institute (NCI) awarded Carnegie Mellon University a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to develop an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with expansion microscopy to enable rapid, large-area 3D imaging at exceptional subcellular detail. The project aims to advance spatial biology in cancer research by visualizing interactions...
This Project Grant award, valued at $497,870 and provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), aims to develop a novel genetically-encoded molecular imaging approach for tracking genome-edited immune cells in vivo. The project will leverage bacterial metallophores as contrast agents to non-invasively monitor the distribution, turnover, and survival of these engineered cells using positron emission tomography (PET) imaging. The first phase will...